Evaluation of biosimilarity of RinGlar® (GEROPHARM LLC, Russia) and Lantus® (Sanofi-Aventis Deutschland GmbH, Germany) using the euglycemic hyperinsulinemic clamp technique in patients with type 1 diabetes: double-blind randomized clinical trial

Evaluation of biosimilarity of RinGlar® (GEROPHARM LLC, Russia) and Lantus® (Sanofi-Aventis Deutschland GmbH, Germany) using the euglycemic hyperinsulinemic clamp technique in patients with type 1 diabetes: double-blind randomized clinical trial

Background: Prevention of the development of micro-and macrovascular complications in patients with diabetes melli-tus (DM) encouraged the search for insulin analogues that allow imitating, as close as possible, a normal physiological insulin secretion in healthy people. Biosimilars (bioanalogues of...

Full description

Bibliographic Details
Main Authors: Alexander Y. Mayorov, Roman V. Drai, Tatiana L. Karonova, Olga I. Avdeeva, Igor E. Makarenko, Ekaterina O. Koksharova, Ekaterina Е. Mishina, Yulia А. Sevastyanova, Olena V. Afonkina
Format: Article
Language:English
Published: Endocrinology Research Centre 2020-12-01
Series:Сахарный диабет
Subjects:
insulin glargin
biosimilar
pharmacokinetics
pharmacodynamics
comparability
glucose infusion rate
ringlar
lantus
Online Access:https://www.dia-endojournals.ru/jour/article/view/10095

Internet

https://www.dia-endojournals.ru/jour/article/view/10095

Similar Items